High radiotherapy dose improves prospects for children with brain cancer

April 25, 2015, European Society for Radiotherapy and Oncology

Two studies to be presented today (Sunday) at the 3rd ESTRO Forum in Barcelona, Spain, show that increasing the dose of radiotherapy given to children with an intracranial ependymoma, a form of cancer of the central nervous system, can significantly improve their survival.

Malignant ependymoma, which develops in the cells that line the hollow cavities of the brain, is normally treated with a combination of surgery and radiotherapy, sometimes with the addition of chemotherapy. Since 2004 a dose of 59.4 Gy1 has been recommended for paediatric cases worldwide, as opposed to the lower (54 Gy) dose that was in use previously, and adding a radiotherapy boost to this can improve outcome yet further in selected cases, the conference will hear today.

Ependymoma is the third most common brain tumour in . With surgery and radiation therapy, the overall five-year survival rate is approximately 70%, but individual prognoses differ considerably according to a number of factors - age, extent of surgery, and radiotherapy technique and dose.

Dr Lorenza Gandola, Head of the Paediatric Radiotherapy Unit at the Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy, will describe how her team developed an innovative strategy for children who still had measurable intracranial ependymoma after surgery. In addition to the 59.4 Gy radiotherapy dose to the tumour bed, they added a boost of 8 Gy, divided into two fractions, to the tumour residue. The researchers used a combination of highly sophisticated radiotherapy techniques in order to deliver the directly to the remaining malignant tissue while sparing normal brain tissue as much as possible. Twenty-four eligible children (median age 4.5 years) out of the 143 in the Italian project received the radiotherapy boost and 15 of them are still alive without disease progression at a median of 51 months after diagnosis.

"Our strategy contributed significantly to obtaining durable local control of disease in these children, and this is more striking because they already had a poorer prognosis after surgery," Dr Gandola will say. "The hypofractionated boost approach represents an effective alternative to surgery in cases where further surgery cannot be performed without the possibility of causing severe and perhaps life-long damage to the child."

No deaths related to the treatment or major toxicity has been reported in the boost group, the researchers say, and the technique will now be the subject of an international clinical trial to be carried out under the auspices of the European paediatric oncology society SIOP, and planned to start later this year.

"We believe that our research has the potential to improve outcomes in children with poor prognosis ependymoma, and we hope that the SIOP trial will confirm them further to the benefit of such patients," Dr Gandola will conclude.

In another presentation, Dr Anne Ducassou, from the Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France, will discuss findings from a study of all 177 children treated for ependymoma in France between 2000 and 2013. The children ranged in age from 1-23, with a median age of five. The researchers studied the characteristic of their disease as revealed by MRI scans, and specifically in those related to metabolism, for example perfusion (the blood flow created in the tumour), and the diffusion of intercellular water molecules, which also reflects the number of cells in the tumour. "We wanted to know whether these metabolic characteristics might have a role in the prognosis of local control of disease and in survival, and whether they might also be able to help us predict relapse, where the disease returns or reoccurs after a period of improvement," Dr Ducassou will say.

All radiation oncologists in France who had treated paediatric patients with ependymoma provided information to Dr Ducassou's team. The researchers found that children with localised disease who had been treated with the high radiation dose of 59.4 Gy, in use since 2004, did better than those who had received the lower dose in use until that date. Of the 177 patients included in the study, the estimated overall survival and progression-free survival (where the disease remains but does not get worse) were 90% and 67% for patients who received a dose above 54 Gy, compared with 79% and 52% who received a lower dose.

"Our work, which involved a large number of children with ependymoma, has confirmed that the treatment we carry out today is better than it was a few years ago, but there is still much work to be done. For example, we found that children younger than three, and those with more aggressive disease had a poorer outcome, and we need to look further at how we can improve their treatment, as well as identifying other children at high risk of relapse," Dr Ducassou will say.

Professor Philip Poortmans, President of ESTRO, commented: "Cancer in children is luckily rare but, when diagnosed, has a major effect of the lives of not only the patient but also the parents and other people close to the child. Recently, research in childhood cancer has focused mainly on the avoidance of late side effects. However, in cases like that of ependymoma, many patients are still not cured and subsequently die from their disease. Therefore it is important to be able to be able recognise accurately those children who are at high-risk for recurrence, and to intensify their treatment.

"Both studies presented here demonstrate that a clear dose-effect relationship exists for tumour control and survival. While the increase from 54 to 59.4 Gy that was adopted first improves disease control and survival in a population-based study, a new study is planned to confirm the results of increasing the dose by a further 8 Gy, delivered with highly directed techniques that give a very localised dose to the target volume with a low dose to the surrounding normal tissues. We hope that this will bring about even better outcomes for these children."

Explore further: Brachytherapy improves survival for inoperable early stage endometrial cancer

More information: 1. A Gray, or Gy, is a measure of radiation dose, defined as the absorption of one joule of energy per kilogram of tissue.

Related Stories

Brachytherapy improves survival for inoperable early stage endometrial cancer

April 25, 2015
Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ...

Studies confirm shorter radiotherapy course best option for women with breast cancer

September 18, 2013
The long-term results of the landmark START trials conclusively confirm that giving radiotherapy as a lower overall dose in fewer, higher doses over a shorter treatment time (hypofractionated) is at least as effective and ...

Research demonstrates potential method to better control lung cancer using radiotherapy

August 28, 2014
Manchester scientists are working out how to safely increase the radiotherapy dose given to lung cancer patients – potentially offering improved local control and survival.

Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment

April 24, 2015
The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to ...

Increased risk of developing lung cancer after radiotherapy for breast cancer

April 7, 2014
Vienna, Austria: Women who have radiotherapy for breast cancer have a small but significantly increased risk of subsequently developing a primary lung tumour, and now research has shown that this risk increases with the amount ...

Analysis shows increased use of HF-WBI for patients with early-stage breast cancer

December 9, 2014
The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive HF-WBI compared to conventionally ...

Recommended for you

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...

Joint supplement speeds melanoma cell growth

March 15, 2018
Chondroitin sulfate, a dietary supplement taken to strengthen joints, can speed the growth of a type of melanoma, according to experiments conducted in cell culture and mouse models.

Improved capture of cancer cells in blood could help track disease

March 15, 2018
Tumor cells circulating throughout the body in blood vessels have long been feared as harbingers of metastasizing cancer - even though most free-floating cancer cells will not go on to establish a new tumor.

Area surrounding a tumor impacts how breast cancer cells grow

March 14, 2018
Cancer is typically thought of as a tumor that needs to be removed or an area that needs to be treated with radiation or chemotherapy. As a physicist and cancer researcher, Joe Gray, Ph.D., thinks differently.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.